Portugal Ana Fereira highlights how the twin factors of people and time have shaped her leadership approach, how she is navigating the challenging generic medicines landscape in Portugal, and why STADA has chosen to put a strategic focus on biosimilars and sustainability. I see STADA becoming one of the top…
Germany A roundup of some of the biggest recent stories from German pharma, including the latest on beleaguered Bayer CEO Werner Baumann, Merck KGaA’s latest investments in France and Germany, and STADA securing the first authorized treatment in Europe for the rare kidney disease immunoglobulin A nephropathy (IgAN). Bayer’s hunt…
Italy EG STADA’s General Manager & Managing Director Italy, Salvatore Butti, explains the company’s strong heritage in generics, the solid presence it is developing in consumer healthcare with new acquisitions from GSK and Sanofi, and its biosimilar and specialties market inroads. In addition, he tells us about the STADA Health Report,…
Spain STADA’s general manager for Spain, Mar Fabregas, reveals how the acquisition of parts of GSK and Sanofi’s portfolio is helping the global generics company better compete in consumer health. In addition, she analyses the biosimilars market in Spain, where the company recently launched Bevacizumab, and comments on the importance of…
Germany After a year of growth and acquisitions, 125-year-old German generics manufacturer STADA is showing a willingness to make bold bets on areas including consumer healthcare, medical cannabis, and research into public opinion on healthcare STADA, based in Bad Vilbel, focuses on a two-pillar strategy consisting of generics, including specialty…
Czech Republic As one of the few pharma companies in the Czech Republic to offer products across the whole healthcare spectrum, including prescription drugs, generics, over-the-counter (OTC) treatments, and food supplements, the 125-year-old German firm STADA has established a strong Czech affiliate in recent times. The beauty of STADA is that…
Serbia Ronald Seeliger, CEO of Hemofarm group, arrived in Serbia during turbulent times in CEE. Following a strict program of reinvestment, local expertise, and innovative strategies, Hemofarm surged forwards, developing into the pharmaceutical powerhouse that we see today. In this interview in the newly renovated offices in Belgrade, Seeliger sheds light…
Pharma Enrique Hausermann, CEO of EG, the Stada Group’s Italian affiliate for its generics business, discusses the progress the company has made since 2009, the promising areas for growth he sees emerging and the market environment for generics companies in Italy today. When we last spoke in 2009, you told us…
See our Cookie Privacy Policy Here